Register Now
Course Information

Plan to attend this complimentary CME symposium that provides an in-depth and up-to-date review of research related to the treatment of patients with MDS, AML, and myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

By attending, you will be able to:

  • Formulate appropriate evaluation and management strategies for patients with aplastic anemia and other bone marrow failures.
  • Define the specific indications for targeted therapies in patients with acute myeloid leukemia (AML), concept of minimal residual disease in AML, and management strategies for adverse events related to novel therapies.
  • Critically review the emerging treatment strategies for patients with low-risk and high-risk myelodysplastic syndromes.
  • List the pharmacologic profiles, efficacy and side effect data, and indications for recently FDA-approved pharmaceuticals and summarize their use in clinical practice.
  • Describe the impact of aging and therapies on the bone marrow microenvironment and its clinical significance on the evolution of clonal hematopoiesis.
  • Summarize the clinical needs and risk-adapted treatment strategies for myeloproliferative neoplasms.
  • List the important advances in pretransplantation risk assessment and transplant techniques for hematopoietic cell transplantation in patients with myeloid malignancies.

Who Should Attend?

The satellite symposium is designed for an international audience including medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

This is a Satellite Symposium organized by the Cleveland Clinic Taussig Cancer Institute Leukemia Program and Aplastic Anemia & MDS International Foundation, preceding the 62nd ASH Annual Meeting.